-+ 0.00%
-+ 0.00%
-+ 0.00%

Meiji Seika Pharma to Buy 7.9% Stake in Arcturus Therapeutics for $50 Million

PUBT·11/16/2026 13:36:14
Meiji Seika Pharma to Buy 7.9% Stake in Arcturus Therapeutics for $50 Million
  • Meiji Seika Pharma will purchase $50 million of Arcturus Therapeutics' unregistered securities for a 7.9% post-transaction stake.
  • The $20.27 per-share purchase price represents an 80% premium.
  • Proceeds will accelerate ARCT-2601 development for OTC deficiency, supporting clinical validation of the LUNAR 2.0 mRNA delivery platform.
  • The expanded collaboration includes an exclusive license to apply ARCT-154 technology in an undisclosed therapeutic area.
  • A memorandum of understanding outlines a potential pandemic preparedness and response collaboration in Japan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-26-001485), on November 16, 2026, and is solely responsible for the information contained therein.